Appendix E. Evidence Tables

Evidence Table 1. Characteristics of included trials

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | Study DesignStudy SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Beatty, 20101Australia | Randomized: 49G1: 25 G2: 24Analyzed: 49G1: 25G2: 24 | RCTOutpatient, urban public hospitals6 months | PSS-SR Baseline, 3 months, & 6 months | Academic |
| Bryant, 20082Australia | Randomized: 90G1: 30G2: 30G3: 30ITT Analyzed: 90G1: 30G2: 30G3: 30 Analyzed (Completers Analysis): 69G1: 25G2: 23G3: 21 | RCTOutpatient, special MH6 months | CAPS-2, Baseline, 5 weeks, 6 months | Government |
| Bryant, 20033Australia | Randomized: 24G1: 12G2: 12Analyzed: 24G1: 12G2: 12 | RCTInpatient6 months | CAPS-2 & IESBaseline, 1 week, & 6 months | Government |
| Bryant, 19984 \*Australia \*Study design changed from NRCT to RCT | Randomized: 24G1: 12G2: 12Analyzed: 24G1: 12G2: 12 | RCTOutpatient, special MH6 months | IESBaseline CIDI PTSD & IES6 weeks & 6 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Size | Study DesignStudy SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Bryant, 20055Australia | Randomized: 87G1: 33G2: 30G3: 24ITT Analyzed: 87G1: 33G2: 30G3: 24Analyzed (Completers Analysis): 69G1: 24G2: 23G3: 22 | RCTOutpatient, special MH6 months | IESBaselineIES & CAPS-25 weeks, 6 months | Government |
| Campfield, 20016Australia | Randomized: 77G1: 36G2: 41Analyzed: 77G1: 36G2: 41 | RCTOutpatient, special MH2 weeks | PDSDebriefing, 2 days post debriefing, 4 days post-debriefing, 2 weeks post-trauma | NR |
| Gamble, 20057Australia | Randomized: 103G1: 50G2: 53Analyzed (Completers Analysis): 103G1: 50G2: 53 | RCTInpatient and Home3 months | MINI-PTSD4-6 weeks, 3 months  | Foundation and academic |
| Melnyk, 20048NA | Randomized: 174G1: 90G2: 84ITT Analyzed: 174G1: 90G2: 84Analyzed (Completers Analysis): 163G1: 87G2: 76 | RCTInpatient12 months | Post-Hospital Stress Index for Parents (post treatment)1 month, 3 months, 6 months, & 12 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | **Study Design****Study Setting****Study Duration** | Primary Outcome& Timing ofAssessment | FundingSource |
| Mulligan, 20129United Kingdom | Randomized: 2523G1: 1144G2: 1379Analyzed 4-6 month ITT: 2443G1: 1108G2: 1335Analyzed 4-6 month completers analysis: G1: 797G2: 819 | RCTOutpatient, military4-6 months | PCL-CBaseline, 4-6 months | NR |
| O'Donnell, 201210Australia | Randomized: 46G1: 24G2: 22Analyzed 6 & 12 month ITT: 46G1: 24G2: 22Analyzed (6 month completers analysis): 42G1: 22G2: 20Analyzed 12 month completers analysis): 31G1: 19G2: 12 | RCTOutpatient, special MH12 months | CAPSBaseline, 6 months, 12 months | Government and Foundation |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | **Study Design****Study Setting****Study Duration** | Primary Outcome& Timing ofAssessment | FundingSource |
| Rose, 199911United Kingdom | Randomized: 157G1: 54G2: 52G3: 51Analyzed (completers analysis): 92G1: NRG2: NRG3: NRITT Analyzed: 157G1: 54G2: 52G3: 51 | RCTCommunity6 months a | PSS-SR & IESBaseline, 6 monthsa | Government |
| Rothbaum, 201212United States | Randomized: 137G1: 69G2: 68Analyzed 4 weeks ITT:b 137G1: 69G2: 68 | RCTInpatient and outpatient 4 weeks b | PDS & PSS-IBaseline, 4 weeks b | Government |
| Ryding, 200413Sweden | Randomized:162G1: 89G2: 73Analyzed: 147G1: 82G2: 65 | RCTInpatient6 months | IES6 months | Foundation/non-profit |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | **Study Design****Study Setting****Study Duration** | Primary Outcome& Timing ofAssessment | FundingSource |
| Shalev, 201114Israel | Randomized: 242G1: 63G2: 40G3: 23G4: 23G5: 93Analyzed: 180G1: 52G2: 35G3: 19G4: 17G5: 57 | RCTOutpatient, special MH9 months | CAPSBaseline, 5 months, & 9 months | Foundation, Pharmaceutical, and Government |
| Sijbrandij, 200615Netherlands | Randomized: 236G1: 76G2: 79G3: 81ITT Analyzed: 236G1: 76G2: 79G3: 81 | RCTOutpatient, special MH6 Months | SI-PTSDBaseline, 2 weeks, 6 weeks, & 6 months | NR |
| Treggiari, 200916Switzerland | Randomized: 137G1: 69G2: 68Analyzed:129G1: 65G2: 64 | RCTInpatient4 weeks | PCL & IES-RBaseline & 4 weeks | Foundation |
| Weis, 200617Germany | Randomized: 36G1: NRG2: NRAnalyzed: 28G1: 14G2: 14 | RCTInpatient6 months | PTSS-106 months | NR |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | **Study Design****Study Setting****Study Duration** | Primary Outcome& Timing ofAssessment | FundingSource |
| Wong, Under review18United States | Randomized: 99G1: 52G2: 47Analyzed 1 month completers analysis: 79G1: 42G2: 37 | RCTInpatient1 month | PCLBaseline, 1 month | NR |
| Zatzick, In press19United States | Randomized: 207G1: 104G2: 103Analyzed 1 month ITT: 207G1: 104G2: 103Analyzed 1 month completers analysis: 176G1: 86G2: 90Analyzed 3 months ITT: 207G1: 104G2: 103Analyzed 3 months completers analysis: 164G1: 81G2: 83Analyzed 6 months ITT: 207G1: 104G2: 103Analyzed 6 months completers analysis: 162G1: 86G2: 76 | RCTInpatient and outpatient 12 months | CAPS & PCL-CBaseline, 1 month, 3 months, 6 months, 9 months, & 12 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year****Country** | **Group Sample Size** | **Study Design****Study Setting****Study Duration** | Primary Outcome& Timing ofAssessment | FundingSource |
| Zatzick, In press19(continued) | Analyzed 9 months ITT: 207G1: 104G2: 103Analyzed 9 months completers analysis: 155G1: 83G2: 72Analyzed 12 months ITT: 207G1: 104G2: 103Analyzed 12 months completers analysis: 167G1: 87G2: 80 |  |  |  |

a Followup was also conducted at 11 months, but we rated all 11-month outcomes as having a high risk of bias because of high overall attrition (>30%) at that timepoint and therefore do not report any of those outcomes.

b Followup was also conducted at 12 weeks, but we rated all 12-week outcomes as having a high risk of bias because of high overall attrition (>30%) at that timepoint and therefore do not report any of those outcomes.

Abbreviations: CAPS = Clinician Administered PTSD Scale; CAPS-2 = Clinician Administered PTSD Scale-2; CIDI PTSD = Composite International Diagnostic Interview PTSD module; G = group; IES = Impact of Event Scale; IES-R = Impact of Event Scale-Revised; ITT = intent-to-treat analysis; MH = mental health; MINI-PTSD = Mini-International Neuropsychiatric Interview-Post-Traumatic Stress Disorder Module; NA = not applicable; NR = not reported; NRCT = nonrandomized controlled trial; PCL = Posttraumatic Stress Disorder Checklist; PCL-C = Posttraumatic Stress Disorder Checklist-Civilian Version; PDS = Posttraumatic Stress Diagnostic Scale; PTSD = posttraumatic stress disorder; PSS-I = Posttraumatic Stress Scale-Interview version; PSS-SR = Posttraumatic Stress Scale-Self-Report version; PTSS-10 = Posttraumatic Stress Symptom 10 Question Inventory; RCT = randomized controlled trial; SI-PTSD = Structured Interview for PTSD